A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

BACKGROUND: This double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly®), an infliximab biosimilar, vs infliximab (Remicade®) reference product sourced from the European Union (...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B., Alten, Rieke, Kameda, Hideto, Hala, Tomas, Radominski, Sebastiao C., Rehman, Muhammad I., Palaparthy, Ramesh, Schumacher, Karl, Schmitt, Susanne, Hua, Steven Y., Ianos, Claudia, Lea Sewell, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063022/
https://www.ncbi.nlm.nih.gov/pubmed/30053896
http://dx.doi.org/10.1186/s13075-018-1646-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063022/
https://www.ncbi.nlm.nih.gov/pubmed/30053896
http://dx.doi.org/10.1186/s13075-018-1646-4

Ejemplares similares